Daprodustat: First Approval

Drugs. 2020 Sep;80(14):1491-1497. doi: 10.1007/s40265-020-01384-y.


Daprodustat (DUVROQ) is a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (PHD) developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease (CKD). Inhibition of PHD prevents degradation of hypoxia-inducible factor (HIF), leading to the production of erythropoietin and subsequent induction of erythropoiesis. In June, daprodustat received its first approval in Japan for the treatment of renal anaemia. Clinical studies of daprodustat are underway in multiple countries worldwide. This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.

Publication types

  • Review

MeSH terms

  • Anemia / drug therapy*
  • Anemia / metabolism
  • Animals
  • Barbiturates / chemistry
  • Barbiturates / pharmacology*
  • Drug Approval*
  • Glycine / analogs & derivatives*
  • Glycine / chemistry
  • Glycine / pharmacology
  • Humans
  • Japan
  • Molecular Structure
  • Prolyl Hydroxylases / metabolism*
  • Prolyl-Hydroxylase Inhibitors / chemistry
  • Prolyl-Hydroxylase Inhibitors / pharmacology*
  • Renal Insufficiency, Chronic / drug therapy*
  • Renal Insufficiency, Chronic / metabolism


  • Barbiturates
  • GSK1278863
  • Prolyl-Hydroxylase Inhibitors
  • Prolyl Hydroxylases
  • Glycine